conditions

SMC Announces Marketing Agreement with Plato Technologies. Inc.

Source Node:
Time Stamp: April 19, 2024 5:45 AM - Modified On: April 19, 2024 - Published By:
Source Cluster:
Republished By Plato

  BOCA RATON, FL / Plato / Amplifi / April 18,2024 / SMC Entertainment, Inc. ("SMC" or the "Company") (OTC PINK: SMCE) SMC / (PINK:SMCE) is pleased to announce a marketing agreement and collaboration with Plato Technologies Inc. Plato Technologies specializes in AI content disruption and AI management systems. The collaboration will enable the Company to market Plato's platform directly to web and content development teams. The companies have agreed on a revenue sharing agreement after deducting individual client acquisition costs. "This is just the beginning." stated Erik Blum CEO

Soft2Bet inaugurates new offices in Malta

Source Node:
Time Stamp: April 16, 2024 5:30 AM - Modified On: April 16, 2024 - Published By:
Source Cluster:
Republished By Plato

The new Malta office will enable Soft2Bet to welcome more team members and handle its corporate expansion in the best conditions Soft2Bet, a leading casino and sportsbook operator and platform provider, announces an important growth milestone - the official opening of its new offices in The Quad Central business center, one of Malta’s latest and most modern business complexes. Situated in the centre of the island, Soft2Bet’s new office was officially inaugurated on 28 March in the presence of the Hon. Silvio Schembri, Malta's Minister for Economy, Enterprise and Strategic

Crypto.com’s Dubai Entity Receives Full Operational Approval

Source Node:
Time Stamp: April 10, 2024 9:43 AM - Modified On: April 10, 2024 - Published By:
Source Cluster:
Republished By Plato

Crypto.com Exchange for Institutional Investors Launches as First Operational Milestone April 9, 2024, Dubai - Crypto.com, trusted by more than 80 million customers worldwide and the industry leader in regulatory compliance, security and privacy, announced today that its Dubai entity, CRO DAX Middle East FZE, has received full operational approval from Dubai’s Virtual Assets Regulatory Authority (VARA) and is launching the Crypto.com Exchange for institutional investors as its first operational milestone. This operational approval follows Crypto.com’s fulfillment of the pre-operational conditions stipulated in the Virtual Asset Service Provider Licence granted

StakingFarm Introduces a Strategic Blueprint for Crypto Staking Success Amid Market Volatility

Source Node:
Time Stamp: March 20, 2024 8:47 AM - Modified On: March 20, 2024 - Published By:
Source Cluster:
Republished By Plato

  London, England – In an era defined by the digital revolution and the emergence of cryptocurrency as a formidable asset class, StakingFarm is proud to announce its advanced approach to crypto staking, designed to navigate the tumultuous waters of market volatility. This strategic blueprint is not merely a response to the fluctuations inherent in the crypto market; it is a comprehensive guide for investors seeking to maximize their earnings through staking crypto, transforming volatility from a challenge into an opportunity. "Volatility in the crypto market is not a barrier;

D8X Re-Engineers DeFi Derivatives With Launch on Polygon zkEVM

Source Node:
Time Stamp: February 6, 2024 2:04 PM - Modified On: February 6, 2024 - Published By:
Source Cluster:
Republished By Plato

Supported by Polygon Ventures, D8X targets institutional users with next-gen DEX engine, innovative features, novel white-label approach [Zug, Switzerland - Feb. 6, 2024] - D8X, an institutional-grade decentralized exchange (DEX) for derivatives, has launched on Polygon zkEVM, establishing a new benchmark for decentralized finance. With support from Polygon Ventures and other notable partners, D8X reconceives on-chain derivatives, starting from fundamental financial engineering and extending to its novel white-label business-to-business model–a first for Polygon zkEVM. Until now, users seeking the trading experience offered by D8X have had to resort to Centralized

Bitcoin, which goes hand in hand with AI technology, can we expect a continued bright outlook? 

Source Node:
Time Stamp: January 11, 2024 11:30 AM - Modified On: January 11, 2024 - Published By:
Source Cluster:
Republished By Plato

Due to the full-scale introduction of AI technology in 2023, America's big tech companies such as Meta, Amazon, and Twitter are threatening human jobs by laying off more than 100,000 employees a year alone. In the aftermath of this, some experts say that the pace of AI development should be slowed down to prevent further harm to human jobs, but on the other hand, most experts believe that human development should proceed together in a society that coexists with AI, rather than slowing it down. There was also an opinion

Bracket Labs Announces $2 Million Pre-Seed Raise to Support the Launch of its ‘Passages’ Trading Platform

Source Node:
Time Stamp: January 4, 2024 2:04 PM - Modified On: January 4, 2024 - Published By:
Source Cluster:
Republished By Plato

PANAMA CITY FLA – January 4, 2024 – Bracket Labs completed a $2 million pre-seed fundraise round to support the launch of "Passage," a volatility trading product available on the project’s BracketX trading platform. The debut of the range-bound product makes trading long and short volatility entirely on-chain easy for traders of all levels. In June 2023, Bracket Labs completed Binance Labs’ Season 5 Incubation Program and received investment from Binance Labs. In addition to completing the Incubation Program, Bracket Labs completed its pre-seed investment round from other notable crypto

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Zilliqa partners with GMEX ZERO13 to launch consumer-focused carbon offset platform

Source Node:
Time Stamp: September 27, 2023 6:42 AM - Modified On: September 27, 2023 - Published By:
Source Cluster:
Republished By Plato

  LONDON, 27 September 2023 – Zilliqa, a leading layer-1 blockchain offering high-performance, high-security and low-fee solutions, today announces a partnership with GMEX Group and its initiative ZERO13, the digital climate fintech aggregation ecosystem, to launch the first-of-its-kind carbon offset platform that will transform the way that retail customers engage with corporate environmental initiatives. Together, Zilliqa Group and GMEX ZERO13 will deliver a cutting-edge platform that uses the blockchain-based currency, EVP, to represent carbon credit offsets. When they purchase goods or services, customers of brands partnered with Zilliqa will receive

Gain Therapeutics Achieves Remarkable Breakthrough in Parkinson’s Disease Research

Source Node:
Time Stamp: August 29, 2023 8:16 AM - Modified On: August 29, 2023 - Published By:
Source Cluster:
Republished By Plato

Gain Therapeutics, Inc. (Nasdaq: GANX), a pioneering biotechnology company specializing in innovative allosteric small molecule therapies, has made significant strides in the fight against Parkinson's disease (PD). The Company's lead drug candidate, GT-02287, has demonstrated extraordinary potential in mitigating the effects of Parkinson's disease across two distinct preclinical models of the ailment. These findings suggest that GT-02287 has the capacity to alleviate Parkinson's disease pathology and enhance motor function. A notable highlight is the substantial reduction of plasma Neurofilament Light Chain (NfL) levels, an emerging biomarker for neurodegeneration. This advancement